The Division of Schizophrenia Research
The Division of Schizophrenia Research (DSR) was established in 2006 as a collaborative effort between Rutgers-University Behavioral Health Care and the Rutgers-Robert Wood Johnson Medical School Department of Psychiatry. The Division was established so as to provide an infrastructure for conducting applied and basic research into the causes and potential treatments for schizophrenia. Since the DSR's inception, faculty and fellows have received over 12 million dollars in grant support, primarily from the National Institute of Mental Health, but also from NARSAD, the Stanley Medical Research Institute, the American Psychological Foundation, Janssen Pharmaceutica, and Astra-Zeneca. Grant-supported projects have been broad-ranging in topic and methodology. For example, they have investigated visual, memory, and cognitive control processing impairments in schizophrenia via functional neuroimaging; they have longitudinally examined perceptual and cognitive impairments in schizophrenia as a means of predicting illness course; they have probed the effectiveness of cognitive remediation in adults and children with schizophrenia; and they have tested medication effectiveness (e.g., pregnenolone; Consta) for enhancing cognitive functioning. Division faculty and staff have also received funding from the New Jersey Division of Mental Health and Addiction Services (DMHAS) to develop evidence-based practices at state hospitals in New Jersey. In addition, junior UBHC staff are routinely trained on a variety of assessment and intervention methods, including social skills training and cognitive remediation.
Mission of the Division of Schizophrenia Research
The mission of the Division of Schizophrenia Research is to conduct research on the causes, defining characteristics, and treatments of schizophrenia in the service of developing improved methods of assessment and treatment to improve the lives of people with this condition.